Sterling Capital Management LLC lessened its position in PAREXEL International Corporation (NASDAQ:PRXL) by 20.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 393,797 shares of the medical research company’s stock after selling 100,190 shares during the period. Sterling Capital Management LLC owned about 0.78% of PAREXEL International Corporation worth $34,225,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. BlackRock Inc. lifted its position in PAREXEL International Corporation by 22,876.6% during the 1st quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock worth $347,955,000 after buying an additional 5,489,460 shares in the last quarter. Credit Suisse AG lifted its position in PAREXEL International Corporation by 1,897.2% during the 1st quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock worth $132,108,000 after buying an additional 1,988,488 shares in the last quarter. Alpine Associates Management Inc. acquired a new position in PAREXEL International Corporation during the 2nd quarter worth about $113,716,000. CNH Partners LLC acquired a new position in PAREXEL International Corporation during the 2nd quarter worth about $109,948,000. Finally, Nomura Holdings Inc. lifted its position in PAREXEL International Corporation by 189.6% during the 1st quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock worth $87,088,000 after buying an additional 904,236 shares in the last quarter. Institutional investors own 87.45% of the company’s stock.
Shares of PAREXEL International Corporation (PRXL) traded down 0.02% during mid-day trading on Thursday, hitting $88.08. The stock had a trading volume of 7,021,106 shares. PAREXEL International Corporation has a 1-year low of $51.16 and a 1-year high of $88.10. The firm has a market capitalization of $4.50 billion, a PE ratio of 42.76 and a beta of 0.77. The stock’s 50-day moving average is $87.85 and its 200-day moving average is $79.27.
PAREXEL International Corporation (NASDAQ:PRXL) last posted its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same period in the previous year, the firm earned $0.94 earnings per share. Equities analysts expect that PAREXEL International Corporation will post $4.06 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “PAREXEL International Corporation (PRXL) Stake Lowered by Sterling Capital Management LLC” was first published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/10/12/parexel-international-corporation-prxl-stake-lowered-by-sterling-capital-management-llc.html.
Several brokerages recently issued reports on PRXL. Zacks Investment Research upgraded shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research report on Thursday, August 31st. BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Jefferies Group LLC reiterated a “hold” rating and set a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Barclays PLC downgraded shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research report on Tuesday, June 20th. Finally, Raymond James Financial, Inc. upgraded shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the stock. PAREXEL International Corporation presently has an average rating of “Hold” and an average price target of $75.92.
About PAREXEL International Corporation
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).
What are top analysts saying about PAREXEL International Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PAREXEL International Corporation and related companies.